Drug updated on 9/4/2024
Dosage Form | Tablet (oral; 3 mg) |
Drug Class | Guanylate cyclase-C agonists |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.
Latest News
Summary
- Trulance (plecanatide) is indicated for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Diphenyl Methane Laxatives (Bisacodyl and Sodium Picosulfate): At 4 weeks, these laxatives were ranked first for failure to achieve three or more complete spontaneous bowel movements (CSBMs) per week (RR 0.55, 95% CI 0.48-0.63, P-score 0.99) and for failure to achieve an increase of one or more CSBM per week from baseline (RR 0.44, 95% CI 0.37-0.54, P-score 0.99).
- Prucalopride: At 12 weeks, prucalopride ranked first for failure to achieve three or more CSBMs per week (RR 0.82, 95% CI 0.78-0.86, P-score 0.96) and for failure to achieve an increase of one or more CSBM per week from baseline (RR 0.74, 95% CI 0.66-0.83, P-score 0.79).
- Linaclotide: Showed similar efficacy to prucalopride 2 mg once daily at 12 weeks for failure to achieve an increase of one or more CSBM per week from baseline (P-score 0.76 for linaclotide, 0.71 for prucalopride).
- There is no safety information available in the reviewed studies for plecanatide (Trulance).
- Bisacodyl ranked lowest for safety due to the highest total number of adverse events and abdominal pain (P-score 0.08).
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Trulance (Plecanatide) Prescribing Information. | 2021 | Salix Pharmaceuticals, Bridgewater, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. | 2019 | The Lancet Gastroenterology & Hepatology |